Terms: = Prostate cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Treatment
80 results:
1. Case Report: Targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer.
Zelba H; Rabsteyn A; Bartsch O; Kyzirakos C; Kayser S; Seibold M; Harter J; Latzer P; Hadaschik D; Battke F; Golf A; Rettig MB; Biskup S
Front Immunol; 2023; 14():1271449. PubMed ID: 37920460
[TBL] [Abstract] [Full Text] [Related]
2. A CXCR4 inhibitor (balixafortide) enhances docetaxel-mediated antitumor activity in a murine model of prostate cancer bone metastasis.
Robinson T; Escara-Wilke J; Dai J; Zimmermann J; Keller ET
Prostate; 2023 Sep; 83(13):1247-1254. PubMed ID: 37244751
[TBL] [Abstract] [Full Text] [Related]
3. Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer.
Karbach J; Kiselicki D; Brand K; Wahle C; Sinelnikov E; Gustavus D; Hoffmeister H; Prisack HB; Atmaca A; Jäger E
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36627144
[TBL] [Abstract] [Full Text] [Related]
4. Generation and Functional Characterization of PLAP CAR-T Cells against Cervical cancer Cells.
Yekehfallah V; Pahlavanneshan S; Sayadmanesh A; Momtahan Z; Ma B; Basiri M
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139135
[TBL] [Abstract] [Full Text] [Related]
5. Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution.
Lu K; Chiu KY; Cheng CL
Cancer Treat Res; 2022; 183():201-223. PubMed ID: 35551661
[TBL] [Abstract] [Full Text] [Related]
6. Development of cancer Immunotherapies.
DeLucia DC; Lee JK
Cancer Treat Res; 2022; 183():1-48. PubMed ID: 35551655
[TBL] [Abstract] [Full Text] [Related]
7. Active Ingredients from
Yeh TH; Lin JY
Curr Issues Mol Biol; 2021 Aug; 43(2):996-1018. PubMed ID: 34563040
[TBL] [Abstract] [Full Text] [Related]
8. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC).
Pachynski RK; Morishima C; Szmulewitz R; Harshman L; Appleman L; Monk P; Bitting RL; Kucuk O; Millard F; Seigne JD; Fling SP; Maecker HT; Duault C; Ramchurren N; Hess B; D'Amico L; Lacroix A; Kaiser JC; Morre M; Grégoire A; Cheever M; Yu EY; Fong L
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452927
[TBL] [Abstract] [Full Text] [Related]
9. The capacity of CD4
Holmen Olofsson G; Pedersen SR; Aehnlich P; Svane IM; Idorn M; Thor Straten P
Cytotherapy; 2021 Jul; 23(7):582-589. PubMed ID: 33785258
[TBL] [Abstract] [Full Text] [Related]
10. Evaluation of cytokine expression and circulating immune cell subsets as potential parameters of acute radiation toxicity in prostate cancer patients.
Stanojković TP; Matić IZ; Petrović N; Stanković V; Kopčalić K; Besu I; Đorđić Crnogorac M; Mališić E; Mirjačić-Martinović K; Vuletić A; Bukumirić Z; Žižak Ž; Veldwijk M; Herskind C; Nikitović M
Sci Rep; 2020 Nov; 10(1):19002. PubMed ID: 33149212
[TBL] [Abstract] [Full Text] [Related]
11. Proinflammatory cytokine profile is critical in autocrine GH-triggered curcumin resistance engulf by atiprimod cotreatment in MCF-7 and MDA-MB-231 breast cancer cells.
Coker-Gurkan A; Ozakaltun B; Akdeniz BS; Ergen B; Obakan-Yerlikaya P; Akkoc T; Arisan ED
Mol Biol Rep; 2020 Nov; 47(11):8797-8808. PubMed ID: 33130987
[TBL] [Abstract] [Full Text] [Related]
12. The Immunotherapy Landscape in Renal Cell Carcinoma.
Brown LC; Desai K; Zhang T; Ornstein MC
BioDrugs; 2020 Dec; 34(6):733-748. PubMed ID: 33048299
[TBL] [Abstract] [Full Text] [Related]
13. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer.
Parriott G; Deal K; Crean S; Richardson E; Nylen E; Barber A
Immunology; 2020 Jul; 160(3):280-294. PubMed ID: 32144940
[TBL] [Abstract] [Full Text] [Related]
14. il-23 and PSMA-targeted duo-CAR T cells in prostate cancer Eradication in a preclinical model.
Wang D; Shao Y; Zhang X; Lu G; Liu B
J Transl Med; 2020 Jan; 18(1):23. PubMed ID: 31937346
[TBL] [Abstract] [Full Text] [Related]
15. treatment of Metastatic or High-Risk Solid cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports.
Nicolini A; Ferrari P; Morganti R; Carpi A
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795079
[TBL] [Abstract] [Full Text] [Related]
16. Molecular Markers of Regulatory T Cells in cancer Immunotherapy with Special Focus on Acute Myeloid Leukemia (AML) - A Systematic Review.
Kaboli PJ; Zhang L; Xiang S; Shen J; Li M; Zhao Y; Wu X; Zhao Q; Zhang H; Lin L; Yin J; Wu Y; Wan L; Yi T; Li X; Cho CH; Li J; Xiao Z; Wen Q
Curr Med Chem; 2020; 27(28):4673-4698. PubMed ID: 31584362
[TBL] [Abstract] [Full Text] [Related]
17. New therapy with XLQ
Yang F; Meng L; Han P; Chen D; Wang M; Jiang Y; Wu Y; Wu Y; Xing N
J Cell Physiol; 2019 Aug; 234(10):17570-17577. PubMed ID: 30790289
[TBL] [Abstract] [Full Text] [Related]
18. Phenotype and Function of Activated Natural Killer Cells From Patients With prostate cancer: Patient-Dependent Responses to Priming and il-2 Activation.
Hood SP; Foulds GA; Imrie H; Reeder S; McArdle SEB; Khan M; Pockley AG
Front Immunol; 2018; 9():3169. PubMed ID: 30761160
[No Abstract] [Full Text] [Related]
19. Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers.
Feng S; Cheng X; Zhang L; Lu X; Chaudhary S; Teng R; Frederickson C; Champion MM; Zhao R; Cheng L; Gong Y; Deng H; Lu X
Proc Natl Acad Sci U S A; 2018 Oct; 115(40):10094-10099. PubMed ID: 30232256
[TBL] [Abstract] [Full Text] [Related]
20. Phase I Trial of Anti-PSMA Designer CAR-T Cells in prostate cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response.
Junghans RP; Ma Q; Rathore R; Gomes EM; Bais AJ; Lo AS; Abedi M; Davies RA; Cabral HJ; Al-Homsi AS; Cohen SI
Prostate; 2016 Oct; 76(14):1257-70. PubMed ID: 27324746
[TBL] [Abstract] [Full Text] [Related]
[Next]
